Phase I study of KRN330 monoclonal antibody in patients with colorectal cancer
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2016
At a glance
- Drugs KRN 330 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- 26 Feb 2009 New source identified and integrated (Vanderbilt-Ingram Cancer Center registry record).
- 05 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jan 2008 New trial record.